Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-001179
Filing Date
2026-04-30
Accepted
2026-04-30 14:21:51
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5705
  Complete submission text file 0002100119-26-001179.txt   7411
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Subject) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88828 | Film No.: 26923391
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G